FN2 Earnings Intelligence
Edwards Lifesciences Corporation financials
Edwards Lifesciences Corporation (EW) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $862.8 | $769 | $1,144 | $3,045.2 | $2,938 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $5,232.5 | $5,382.4 | $6,004.8 | $5,439.5 | $6,067.6 | $6,763.5 | $7,435.6 |
| % Growth | 19.3% | 2.9% | 11.6% | -9.4% | 11.5% | 11.5% | 9.9% |
| Gross Profit | $3,983.6 | $4,302 | $4,625 | $4,322 | $4,733.4 | - | - |
| % Margin | 76.1% | 79.9% | 77.0% | 79.5% | 78.0% | - | - |
| EBITDA | $1,825.1 | $1,888.1 | $1,679 | $1,533.9 | $1,420.8 | - | - |
| % Margin | 34.9% | 35.1% | 28.0% | 28.2% | 23.4% | - | - |
| Net Income | $1,503.1 | $1,521.9 | $1,402.4 | $4,174.6 | $1,073.5 | - | - |
| % Margin | 28.7% | 28.3% | 23.4% | 76.7% | 17.7% | - | - |
| Diluted EPS | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 | $3.00 | $3.38 |
| % Growth | 83.1% | 2.5% | -5.7% | 203.0% | -73.7% | 64.1% | 12.6% |
| Operating Cash Flow | $1,732.1 | $1,218.2 | $895.8 | $542.3 | $1,595.2 | - | - |
| CapEx | $325.8 | $244.6 | $253 | $252.4 | $260.2 | - | - |
| Free Cash Flow | $1,406.3 | $973.6 | $642.8 | $289.9 | $1,335 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $5,232.5 | $5,382.4 | $6,004.8 | $5,439.5 | $6,067.6 | $6,763.5 | $7,435.6 |
| Gross Profit | $3,983.6 | $4,302 | $4,625 | $4,322 | $4,733.4 | - | - |
| EBITDA | $1,825.1 | $1,888.1 | $1,679 | $1,533.9 | $1,420.8 | - | - |
| Net Income | $1,503.1 | $1,521.9 | $1,402.4 | $4,174.6 | $1,073.5 | - | - |
| Diluted EPS | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 | $3.00 | $3.38 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $862.8 | $769 | $1,144 | $3,045.2 | $2,938 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $595.7 | $596.3 | $597 | $597.7 | $598.3 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1,732.1 | $1,218.2 | $895.8 | $542.3 | $1,595.2 |
| Capital Expenditure | $325.8 | $244.6 | $253 | $252.4 | $260.2 |
| Free Cash Flow | $1,406.3 | $973.6 | $642.8 | $289.9 | $1,335 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 19.3% | 2.9% | 11.6% | -9.4% | 11.5% |
| Gross Margin | 76.1% | 79.9% | 77.0% | 79.5% | 78.0% |
| EBITDA Margin | 34.9% | 35.1% | 28.0% | 28.2% | 23.4% |
| Net Margin | 28.7% | 28.3% | 23.4% | 76.7% | 17.7% |
| FCF Margin | 26.9% | 18.1% | 10.7% | 5.3% | 22.0% |
| Diluted EPS Growth | 83.1% | 2.5% | -5.7% | 203.0% | -73.7% |